BeOne Medicines Ltd. (BEIGF)

Market Cap	30.35B
Revenue (ttm)	4.18B
Net Income (ttm)	-394.86M
Shares Out	n/a
EPS (ttm)	-3.75
PE Ratio	n/a
Forward PE	99.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	499
Open	15.95
Previous Close	19.01
Day's Range	15.95 - 15.95
52-Week Range	11.00 - 20.61
Beta	0.30
RSI	46.61
Earnings Date	May 14, 2025

About BeOne Medicines

BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: OTCMKTS
• Ticker Symbol: BEIGF

Financial Performance

In 2024, BeOne Medicines's revenue was 27.81 billion, an increase of 59.51% compared to the previous year's 17.43 billion. Losses were -4.71 billion, -24.72% less than in 2023.

Financial numbers in CNY